Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | MAOB | P27338 | 7/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NOS1 | P29475 | 1/20 | 0.44 |
| ▸ | HMOX2 | P30519 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30544716 | 1.00 | ALDH1A1 (0.53) | ALDH1A1KDM4EMAOBRAB9AHTT | |
| SCHEMBL30594499 | 0.91 | ALDH1A1 (0.56) | ALDH1A1KDM4EMAOBRAB9AHTT | |
| SCHEMBL22367610 | 0.87 | ALDH1A1 (0.44) | ALDH1A1KDM4EL3MBTL1KMT2A | |
| SCHEMBL13883739 | 0.82 | MAOB (0.64) | ALDH1A1KDM4EMAOBRAB9AHTT | |
| SCHEMBL2794233 | 0.82 | MAOB (0.51) | ALDH1A1KDM4EMAOBRAB9AHTT | |
| SCHEMBL31573499 | 0.81 | MAOB (0.55) | ALDH1A1KDM4EMAOBRAB9AHTT | |
| SCHEMBL472525 | 0.81 | MAOB (0.55) | ALDH1A1KDM4EMAOBRAB9AHTT | |
| SCHEMBL7162438 | 0.81 | MAOB (0.62) | ALDH1A1KDM4EMAOBRAB9AHTT | |
| SCHEMBL5263425 | 0.79 | MAOB (0.61) | ALDH1A1KDM4EMAOBRAB9AHTT | |
| SCHEMBL2801030 | 0.79 | MAOB (0.60) | ALDH1A1KDM4EMAOBRAB9AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116621723-A | Method for oxidizing non-activated end group olefin into secondary alcohol | 江苏科技大学 | 2023-08-22 | — | — | CN | disclosed |
| US-20100168194-A1 | Amino-5-[4-(difluoromethoxy)phenyl]-5-phenylimidazolone Compounds For The Inhibition Of Beta-secretase | WYETH LLC (US) | 2010-07-01 | — | — | US | disclosed |
| US-7723368-B2 | Amino-5-[4-(difluoromethoxy)phenyl]-5-phenylimidazolone compounds for the inhibition of beta-secretase | WYETH LLC (US) | 2010-05-25 | — | — | US | disclosed |
| EP-2144884-A2 | AMINO-5-[4-(DIFLUOROMETHOXY)PHENYL]-5-PHENYLIMIDAZOLONE COMPOUNDS FOR THE INHIBITION OF BETA-SECRETASE | Wyeth a Corporation of the State of Delaware (US) | 2010-01-20 | — | — | EP | disclosed |
| US-20090048320-A1 | AMINO-5-[4-(DIFLUOROMETHOXY)PHENYL]-5-PHENYLIMIDAZOLONE COMPOUNDS FOR THE INHIBITION OF BETA-SECRETASE | WYETH (US) | 2009-02-19 | — | — | US | disclosed |
| WO-2008118379-A2 | AMINO-5-[4-(DIFLUOROMETHOXY)PHENYL]-5-PHENYLIMIDAZOLONE COMPOUNDS FOR THE INHIBITION OF β-SECRETASE | WYETH (US) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048320-A1 | AMINO-5-[4-(DIFLUOROMETHOXY)PHENYL]-5-PHENYLIMIDAZOLONE COMPOUNDS FOR THE INHIBITION OF BETA-SECRETASE | BACE1, BACE2, APP | ALDH1A1 3041/4885KDM4E 826/4885MAOB 725/4885 |
| US-20100168194-A1 | Amino-5-[4-(difluoromethoxy)phenyl]-5-phenylimidazolone Compounds For The Inhibition Of Beta-secretase | BACE1, BACE2, APP | ALDH1A1 3041/4885KDM4E 826/4885MAOB 725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.